Neonatal pneumococcal conjugate vaccine immunization primes T cells for preferential Th2 cytokine expression: A randomized controlled trial in Papua New Guinea  by van den Biggelaar, Anita. H.J. et al.
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The effects of neonatal immunization with 7-valent pneumococcal conjugate vaccine (7vPCV) on devel-
opment of T-cellmemory andgeneral immunematurationwere studied in a cohort of PapuaNewGuineaneceived in revised form 18 December 2008
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eywords:
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newborns. Neonatal 7vPCV priming (followed by a dose at 1 and 2 months of age) was associated with
enhanced Th2, but not Th1, cytokine responses to CRM197 compared to 7vPCV at 1 and 2 months of age
only. T cell responses to non-7vPCV vaccine antigens were similar in all groups, but TLR-mediated IL-6
and IL-10 responses were enhanced in 7vPCV vaccinated compared to controls. Neonatal 7vPCV vacci-
nation primes T cell responses with a polarization towards Th2 with no bystander effects on other T cell
responses.
.
eonatal
cells
. Introduction
Every year about 1 million children under 5 years of age die of
neumococcal pneumonia, meningitis or sepsis, mostly in devel-
ping countries [1]. Immunization with a 7-valent or 9-valent
neumococcal conjugate vaccine (7vPCV or 9vPCV) has been found
o be efﬁcacious in reducing severe morbidity and mortality in
ndustrialized and resource-poor countrieswhengiven at the age of
weeks or older [2–5]. However, Streptococcus pneumoniae remains
n important cause of serious morbidity and mortality in children
n the ﬁrst 3 months of life [6–8]. In the highlands of Papua New
uinea (PNG), where this study was performed, the mortality rate
or pneumonia in infants is 25/1000/year [9] and S. pneumoniae
ccounts for almost half of all bacteraemic pneumonia (as well
s meningitis) cases [10,11]. Accelerated immunization schedules,
ncluding neonatal vaccination, should therefore be considered in
igh-risk populations to induce the earliest possible protection
gainst invasive pneumococcal disease.In contrast to pneumococcal polysaccharide vaccines, conjugate
accines can elicit memory responses, even in young children. The
emory T cell response that is induced against the carrier pro-
ein (in 7vPCV this is a non-toxic diphtheria toxin mutant protein,
∗ Corresponding author. Tel.: +61 8 9489 7919; fax: +61 8 9489 7700.
E-mail address: Anitav@ichr.uwa.edu.au (Anita.H.J. van den Biggelaar).
264-410X © 2008 Elsevier Ltd.
oi:10.1016/j.vaccine.2008.12.046
Open access under CC BY license.© 2008 Elsevier Ltd.
CRM197) is a key factor in the induction of long term protection by
providing help to polysaccharide-speciﬁc memory B cell responses
[12–14]. In human newborns and young infants T cell responses are
immature and characterized by deﬁcient T helper 1 (Th1) responses
[15–18] and a reduced capacity to induce T cellmemory [19]. There-
fore neonatal conjugate vaccination could fail to provide long-term
protection, as shown in neonatal mice that were unsuccessful in
producing T cell responses upon vaccination [20], or may result in
the induction of tolerance to subsequent vaccination or infection.
However, under appropriate priming conditions, neonatal T cells
do have the intrinsic capacity to generate memory T(h1) responses
as has been shown following neonatal BCG vaccination [21,22].
With respect to conjugate vaccines, the effect of neonatal immu-
nization on T-cell responses has not been evaluated. Studies that
measured antibody responses following neonatal immunization
with Haemophilus inﬂuenzae type b (Hib) conjugate vaccines have
reported inconsistent ﬁndings including evidence of B-cell priming
[23,24] and induction of hyporesponsiveness [25], depending on
the carrier protein used. Furthermore, T cell responsiveness varies
within and possibly between populations as a result of variation
in population genetics and environmental factors [26–31]. There-
Open access under CC BY licensefore, before considering large-scale randomized controlled trials, it
is essential to determine the safety and immunogenicity of neona-
tal pneumococcal conjugate vaccination in high-risk populations,
including its effects on vaccine-speciﬁc T-cell responses and on the
developing T cell system in general.
t al. / V
t
r
a
i
e
c
p
c
o
2
2
w
1
t
l
t
r
l
d
t
t
n
W
m
e
2
r
a
o
t
2
n
b
m
E
p
a
t
i
v
m
o
v
s
b
c
R
v
(
d
s
tAnita.H.J. van den Biggelaar e
Herewe report on the effect of a primary dose of 7vPCV vaccina-
ion at birth, followed by a dose at 1 and 2 months of age, on T cell
esponses at 3 months of age. This study was undertaken as part of
n ongoing open randomized controlled safety and immunogenic-
ty trial with 7vPCV in PNG. Our primary aim was to determine the
ffect of neonatal 7vPCV vaccination on the activation of protein
arrier-speciﬁc T cell responses. Secondary aims were to evaluate
otential non-speciﬁc effects on cellular immune responses to con-
omitant vaccines and interference with the postnatal maturation
f the T cell and innate immune system.
. Materials and methods
.1. Study area and participants
The Asaro Valley in the Eastern Highlands Province of PNG,
here this study was performed, lies 6◦ south of the equator and at
500–1900m above sea level. Goroka town is the provincial capi-
al. The PNG Institute of Medical Research (PNGIMR) headquarters,
aboratories and small clinic are located next to Goroka Hospital,
he only tertiary hospital in the province. Pregnant women were
ecruited at Goroka Hospital antenatal clinic and also in villages
ocated within an hour’s drive of Goroka town and under monthly
emographic surveillance by PNGIMR local reporters. Inclusion cri-
eria for enrolment of newborns were the intention to remain in
he study area for at least 2 years, a birth weight of at least 2000g,
o acute neonatal infection and no severe congenital abnormality.
hile there was no routine HIV testing, antenatal testing is recom-
ended and children of mothers known to be HIV positive were
xcluded.
.2. Ethical considerations
Assentwas sought fromwomen and their partners at the time of
ecruitment. Written informed consent was obtained after delivery
nd before enrolment of the newborn child. Ethical approval was
btained from the PNG Medical Research Advisory Committee and
hePrincessMargaretHospital EthicsCommittee inPerth,Australia.
.3. Study design
Newbornswere randomizedusing computer-generated random
umber lists to receive three doses of 7vPCV (Prevnar®, Wyeth) at
irth, 1 month and 2 months of age (neonatal group) or at 1, 2 and 3
onthsof age (infant group), or to receiveno7vPCV (control group).
ach dose of 7vPCV contained 20g of CRM197 carrier protein cou-
led to seven pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F)
nd 0.125mg aluminium adjuvant. Laboratory staff was blinded to
he randomization code.
In addition to the study vaccine, all children were to receive the
mmunizations recommended in PNG: Bacillus Calmette-Guérin
accine (BCG) at birth; oral polio vaccine (OPV) at birth, 1, 2 and 3
onths of age; Hepatitis B vaccine (HepB) at birth, 1 and 3 months
f age; andacombinedHib, diphtheria, tetanus,whole cell pertussis
accine (DTwP/Hib) at 1, 2 and 3 months of age. Due to a temporary
hortage of BCG vaccine in PNG, BCGwas givenmore than 72h after
irth to 30 study children (12 neonatal, 7 infant and 11 controls).
A clinical examination was done before each vaccination. Vac-
ination was postponed if children had a temperature >38 ◦C.
esearch nurses visited children 48–96h post-vaccination to inter-
iew parents and examine the children for systemic symptoms
including fever, raised respiratory rate, irritability, drowsiness,
iarrhoea, vomiting and/or rash) and local reactions (tenderness,
welling and/or redness at the vaccination site). Follow-ups outside
his time frame were excluded from this analysis.accine 27 (2009) 1340–1347 1341
2.4. Isolation of peripheral mononuclear cells
Avenous blood sample (1–2.5ml)was collected fromchildren at
3 months of age into a sterile tube containing 100 IU preservative-
free heparin and centrifuged within 2h to separate plasma. Cells
were resuspended inRPMI1640 (Invitrogen-Life Technologies,Mel-
bourne, Australia) containing preservative-free heparin (20U/ml)
and centrifuged over a Ficoll-Hypaque gradient (Lymphoprep,
Alexis-Shield, Oslo, Norway) to isolate peripheral mononuclear
cells (PBMC). PBMC were cryopreserved in 50% heat-inactivated
foetal calf serum (HI-FCS) and 7.5% DMSO and transported to the
Institute of Child Health Research (ICHR) in Perth for further anal-
ysis.
2.5. In vitro PBMC cultures
To assess T-cell responses, PBMC were resuspended in RPMI/5%
heat inactivated human AB serum (Pharmacia Australia Pty. Ltd.,
Sydney, Australia), plated into 96-wells plates (1×106 cells/ml) and
stimulated (in duplicate) with medium (control), CRM197 (kindly
provided by Wyeth Pharmaceuticals, USA) (2.5g/ml) and phyto-
hemagglutinin (PHA; Remel Europe Ltd, Kent, UK) (1g/ml). When
sufﬁcient cellswere available, further stimulationswere performed
with soluble Hepatitis B antigen (HbsAg; ProSpec-Tany Techno-
Gene, Rehovot, Israel) (2.5g/ml), mycobacterium puriﬁed protein
derivative (PPD; CSL, Victoria, Australia) (10g/ml) and tetanus
toxoid (TT; CSL, Victoria, Australia) (0.5 lf/ml). Supernatants were
collected after 96h of culture (48h for PHA).
To measure innate immune responses, PBMC were resus-
pended in RPMI/10% non-heat inactivated FCS (1×106 cells/ml)
and stimulated (single wells) with medium (control), Staphylococ-
cus aureus-derived lipoteichoic acid (LTA, InvivoGen, San Diego,
USA) (2g/ml), polyinosinic–polycytidylic acid (PolyIC, Sigma,
Saint Louis, USA) (50g/ml), Escherichia coli-derived lipopolysac-
charide (LPS, serotype R515, Alexis Biochemicals, San Diego, USA)
(5g/ml), and type C oligonucleotide CpG (InvivoGen, SanDiego,
USA) (3g/ml). Supernatants were harvested after 24h and cell
pellets were stored in RNA-later (Ambion, Austin, TX, USA).
2.6. Cytokine protein detection
Supernatantswere stored at 4 ◦C for amaximumof 7 days before
protein levels of IL-5, IL-6, IL-10, IL-13, IFN- and TNF-were mea-
sured by in-house time-resolved ﬂuorometry [32]. Samples with
concentrations below the detection limit were given the value cor-
responding to half the lowest detection concentration: 1.5pg/ml
for IL-5, IL-6, IL-10 and IL-13; 1.75pg/ml for TNF-; and 2pg/ml for
IFN-.
2.7. Quantitative (q)RT-PCR
Total RNA was isolated using the RNAqueous 96 well Kit
(Ambion) according to the manufacturer’s instructions. Reverse
transcription was performed using the Quantitect kit (Qiagen,
USA) according to the manufacturer’s protocol with oligo-dT
(Promega, USA) and Superasin (GeneWorks, Australia). Intron-
spanning primers for IL-23p19, myxovirus resistance protein A
(MxA), Granzyme B and lymphotoxin- were obtained from
http://pga.mgh.harvard.edu/primerbank and designed in-house
using Primer Express Software (Applied Biosystems, USA). Reverse-
transcribed RNA samples were diluted 1/5 and quantitated by
real-time PCR usingQuantiTect SYBRGreenMasterMix (Qiagen) on
the ABI PRISM 7900HT (Applied Biosystems). Copy numbers were
determined by 10-fold serial dilutions of plasmid standards and
normalized to the reference gene UBE2D2 [33].
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.8. Statistical analysis
To compare categorical variables chi-square analysis was
erformed and the Pearson chi-square and Cramer’s V were
alculated for 2×2 and 2×3 tables, respectively. Mann–Whitney
est or Kruskal–Wallis test were used to compare continuous data
n two or three groups, respectively. Cytokine responses were
og10 transformed and data presented as geometric means
GM)± the standard error of the geometric means (SEGM). Where
ndicated, Z-scores were calculated according to the equation:
og10(delta CRM-cytokine) −mean of log10(delta CRM-cytokine)/standard
eviation of log10(delta CRM-cytokine).
To study the effect of age at BCG vaccination on T cell
ytokine responses at 3 months (Z-scores), linear regression analy-
is (ANOVA) was used.
Differences were considered signiﬁcant if the p-value was
maller or equal to 0.05.
. Results
.1. Study population
Of the 488 pregnant women who assented, 318 newborns were
nrolled and randomized to the neonatal 7vPCVgroup (n=104), the
nfant 7vPCV group (n=105), or the control group (n=109). Within
he 3 month study period, 36 children had left the study or were
xcluded: 1 child had died of pneumonia (infant group), 25 children
ere withdrawn or lost to follow up (10 neonatal, 5 infant, 10 con-
rol group), 5 children had protocol violations recorded (2 neonatal,
infant, 2 control group), and 5 children had a late detection of
xclusion criteria including HIV and congenital heart disease (2
eonatal, 3 control group). Of the remaining 282 children sufﬁcient
able 1
opulation description.
Neonatal (n=68)
other characteristics
Mean age (years) 25.8 (5.4)
Gravida: 1 27%
Gravida: 2 35%
Gravida: 3 21%
Gravida: 4+ 17%
Delivery by caesarean 3%
Smoking in pregnancy 8%
Tetanus vaccination 93%
ewborn characteristics
Male 44%
Mean gestational age (weeks) 39.4 (1.3)
Mean birth weight (kg) 3.2 (0.4)
Mean birth length (cm) 49.7 (3.2)
Mean head circumference (cm) 33.2 (1.4)
Mean weight at age 3 months (kg) 6.3 (0.8)
ean age at vaccination, days
BCG 9.8 (30.1)
7vPCV – 1 1.3 (0.9)
7vPCV – 2 30.2 (2.8)
7vPCV – 3 62.5 (5.8)
Hepatitis B – 1 0.9 (1.0)
Hepatitis B – 2 30.2 (2.8)
Hepatitis B – 3 93.5 (9.3)
OPV – 1 2.2 (2.6)
OPV – 2 31.7 (6.9)
OPV – 3 63.2 (7.4)
OPV – 4 94.7 (9.3)
DTwP/Hib – 1 30.1 (3.3)
DTwP/Hib – 2 62.4 (5.7)
DTwP/Hib – 3 93.5 (9.3)
ontinuous data are represented as mean (standard deviation). BCG, Bacillus Calmette-G
accine; DTwP/Hib, combined Haemophilus inﬂuenzae type b diphtheria, tetanus, whole caccine 27 (2009) 1340–1347
PBMC for cellular immunological assays (a minimum of 1.5×106
cells) were available for 198 children at 3 months (68 neonatal,
68 infant, 62 control group). Characteristics for these 198 new-
borns and their mothers are summarized in Table 1. There were
no signiﬁcant differences between the three study arms.
3.2. Reactogenicity
Children experienced few local side effects to 7vPCV vaccination
(20/373, 5.4%) and few systemic side effects following any vaccina-
tion between birth and 3 months (52/705, 7.4%). For children in the
neonatal group a total of six local reactions to 7vPCV were recorded
(0/60 at birth, 2/62 at 1 month, 4/59 at 3 months) and for children
in the infant group 14 reactions were recorded (3/63 at 1 month,
and 8/64 at 2 month, and 3/64 at 3 months) (p=0.084). Reactions
predominantly involved tenderness of the vaccination site. Sys-
temic side effects, which predominantly involved irritability, were
recorded in 22 children in the neonatal group after vaccination at
birth, 1month, 2monthsor3months (1/60atbirth, 9/62at1month,
and 7/59 at 2 months, and 5/56 at 3 months), for 16 children in the
infant group (0/61 at birth, 7/63 at 1 month, 5/63 at 2 months, and
4/65 at 3 months), and 14 children in the control group (2/54 at
birth, 6/55 at 1 month, 5/55 at 2 months, and 1/53 at 3 months)
(p=0.387).
To date there have been no serious adverse events related to the
study vaccine.3.3. T-cell responses to the protein carrier
Children in both theneonatal and infant 7vPCVgroups produced
signiﬁcantly higher Th1 (IFN-) and Th2 (IL-5 and IL-13) cytokine
responses at the age of 3 months in response to CRM197 com-
Infant (n=68) Control (n=62) p-Value
25.6 (5.3) 25.2 (5.7) 0.715
30% 37%
21% 28%
21% 15%
27% 20% 0.468
2% 2% 0.807
7% 15% 0.251
88% 93% 0.473
54% 55% 0.373
39.7 (1.2) 39.7 (0.2) 0.299
3.3 (0.4) 3.2 (0.5) 0.457
49.8 (3.8) 50.5 (3.2) 0.459
33.3 (1.8) 33.3 (1.5) 0.872
6.2 (0.9) 6.4 (0.7) 0.358
3.4 (7.6) 2.7 (4.9) 0.780
30.0 (2.8) N/A N/A
61.1 (5.5) N/A N/A
92.7 (7.1) N/A N/A
1.2 (1.8) 1.2 (1.3) 0.547
30.0 (2.8) 30.4 (4.9) 0.684
92.7 (7.1) 90.1 (7.3) 0.185
3.9 (8.7) 4.4 (10.2) 0.169
33.2 (10.8) 32.2 (8.3) 0.774
63.4 (12.0) 62.9 (8.3) 0.500
92.0 (6.6) 94.1 (17.3) 0.301
30.0 (2.8) 30.4 (4.9) 0.723
61.1 (5.5) 61.5 (6.4) 0.398
92.7 (7.1) 92.8 (16.3) 0.406
uerin vaccine; 7vPCV, 7-valent pneumococcal conjugate vaccine; OPV, oral polio
ell pertussis vaccine.
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Fig. 1. T cell responses to 7vPCVand concomitant vaccines. Peripheral bloodmononuclear cellswere cultured in vitrowithmediumonly, or stimulatedwith the vaccine protein
carrier CRM197, the polyclonal phytohemagglutinin (PHA), and vaccine antigens including soluble Hepatitis B antigen (HbsAg), mycobacterium puriﬁed protein derivative
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neonatal group most of the Th1 responders (86%) produced Th2
cytokine responses (IL5-CRM197 and/or IL13-CRM197) in conjunc-
tion, whereas only 14% (6% of the total study group) produced Th1
responses ‘in isolation’ compared to 32% of the Th1 responders in
the infant group (p=0.072) (16% of total infant group) and 78% of
Fig. 2. Co-production of CRM197-speciﬁc Th1 and Th2 responses in neonatal, infantPPD) and tetanus toxoid (TT). Antigen-speciﬁc cytokine responses were calculated
esponses measured in stimulated cell cultures (‘delta concentration’). Represente
hildren randomized to the neonatal (white bar), infant (grey bar) and control grou
**) and 0.05 (*) level.
ared to children in the control group (Fig. 1). CRM197 responses
n the control group are most likely explained by cross-reactivity
ith diphtheria antigen in the DTwP/Hib vaccine. The elevated Th2
ytokine responses in the 7vPCVgroups resulted fromboth a higher
roportion of children being responders and actual higher levels
hat responders produced: 68% and 40% of children in the neona-
al and infant group were IL5-CRM197 responders (as deﬁned by
evels of at least four times their background) compared to 13% in
he control group (p<0.001) and produced (geometric) mean lev-
ls of respectively 63.5pg/ml (SEGM±8.9), 47.7pg/ml (±7.7) and
7.2pg/ml (±5.0) (p=0.045). The same was found for IL13-CRM197:
he proportion of positive responders (levels≥4 times background)
as 68% for the neonatal group, 47% for the infant group and 24%
or the control group (p<0.001) and produced levels (GM± SEGM)
f 94.6pg/ml (±12.89), 68.7pg/ml (±10.7) and 29.6pg/ml (±4.5)
espectively (p<0.001). For IFN-CRM197 nodifferenceswere found
or the proportion of responders (44%, 46% and 44% in the neona-
al, infant and control group respectively) (p=0.947), but positive
esponders in the neonatal (135.4±49.1pg/ml) and infant groups
91.7±33.4pg/ml) produced signiﬁcantly higher levels than those
n the control group (19.0±5.8pg/ml) (p=0.013). The propor-
ion of IL10-CRM197 responders was low and similar for the
hree groups: 6% in the neonatal group, 6% in the infant group
nd 0% in the control group (p=0.150). TNF- responses could
ot be detected (GM is 1.8pg/ml for the neonatal group and
qual to the cut-off value of 1.75pg/ml for the infant and con-
rol groups), which suggests that CRM197 responses were mainly
ognate.IL-5 and IL-13 responses to CRM197 were signiﬁcantly higher
n the neonatal than in the infant group (p=0.002 and p=0.015,
espectively) (Fig. 1). This was explained by signiﬁcant differences
n the proportion of responders (IL5, p=0.001; IL-13, p=0.005)
nd not levels these responders produced (p=0.273 and p=0.185,tracting background levels that were produced in cultures with medium only from
the geometric means (GMs) and standard errors of geometric means (SEGMs) for
k bar). Signiﬁcant differences between groups are indicated at the 0.001 (***), 0.01
respectively). There were no differences for IFN- responses
between the neonatal and infant group.
As illustrated in Fig. 2, there was no difference in the propor-
tion of Th1-CRM197 responders in the three groups, but in theand control groups. Childrenwere considered toproduceTh1 responses to the7vPCV
protein carrier CRM197 when in vitro CRM197-induced IFN- responses were at least
four times the background level, and Th2 responses if CRM197-induced IL-5 and/or
IL-13 responses were at least four times the background. For each study group the
proportion of children with no memory responses (hatched), Th2 without Th1 (light
grey), mixed Th1/Th2 (dark grey) and Th1 without Th2 (black) is presented.
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3ig. 3. TLR-mediated immune responses. PBMCof3-month-old children in theneona
ipoteichoic acid (LTA) (neonatal n=37; infant n=39; control n=33), polyinosinic–po
LPS) (neonatal n=42; infant n=40, control n=35) and oligonucleotide CpG (CpG) (n
rrors of geometric means of ligand speciﬁc cytokine responses (minus background
he Th1 responders in the control group (34% of total control group)
p<0.001).
.4. Bystander effect on T-cell responses
There were no differences in Th1 or Th2 cytokine responses
o PPD (BCG). Th1 and Th2 responses to HbsAg (Hepatits B), TT
DTwP/Hib) and the polyclonal PHA tended to be highest in the
eonatal 7v-PCV group, but this was only signiﬁcant for IL-13
esponses to TT when compared to the infant group (p=0.049)
Fig. 1).
.5. TLR-mediated immune responses
Children in the neonatal and infant 7vPCV vaccination groups
roduced higher IL-10 and IL-6 responses to the TLR ligands
TA (TLR2) (IL-10, p=0.006; IL-6, p=0.053), poly:IC (TLR3) (IL-
0, p=0.015; IL-6, p=0.049) and LPS (TLR4) (IL-10, p=0.052; IL-6,
= 0.028) than the control group (Fig. 3). A similar trend was
een for TNF- responses, but differences were not statistically
igniﬁcant. TLR-mediated IFN- responses were generally higher
n the infant group, but this was only signiﬁcant in response to
pG.
Wefurther investigated thepossiblemodulationofother inﬂam-
atory mediators including type-I interferon, IL-23, Granzyme
and lymphotoxin- in response to LPS stimulation, but otherhan a reduced expression of IL-23 in the 7vPCV vaccination
roups, no differences were found (Fig. 4). All three groups showed
n enhanced release of mature IL-1 in response to LPS stim-
lation, but there were no signiﬁcant differences between the
roups (neonatal 315.5±101.4pg/ml, infant 334.1±163.9pg/ml,
03.6±103.7pg/ml) (p=0.955).hitebar), infant (greybar) andcontrol group (blackbar)were stimulated in vitrowith
dylic acid (Poly:IC) (neonatal n=40; infant n=38; control n=34), lipopolysaccharide
al n=32; infant n=34; control n=27). Bars represent geometric means and standard
nse).
3.6. Effect of BCG immunization
BCG vaccination was delayed (more than 3 days after birth) in
30 study children (12 neonatal, 7 infant and 11 controls). Although
signiﬁcant associations were found between PPD-speciﬁc IL-13
responses at 3 months and the age at which children had received
BCG, there were no signiﬁcant effects with respect to cytokine
responses to CRM197 (Table 2), HbsAg or PHA (data not shown),
either overall orwhen the neonatal groupwas examined separately
(data not shown).
4. Discussion
To our knowledge this study in PNG is the ﬁrst safety and
immunogenicity trial of 7vPCV in human newborns to include
an evaluation of cellular immune responses. We have found that
neonatal 7vPCV immunization is well tolerated, does not induce
tolerance but rather primes carrier protein-speciﬁc T-cell responses
with a preferential expression of Th2 cytokines, and has no detri-
mental effects on general T cell ontogeny.
In line with 7vPCV studies involving adults and toddlers in the
USA [13,14,34], carrierprotein-speciﬁcT-cell responses in3-month-
old PNG children were of a mixed Th1/Th2 phenotype. However,
compared to children immunized with 7vPCV at 1 and 2 months
of age, children primed with a neonatal dose of 7vPCV produced
signiﬁcantly higher Th2, but not Th1, cytokine responses to CRM197.
Moreover, children in the neonatal group generally produced Th1
cytokine responses in conjunctionwith Th2, and not ‘in isolation’ as
wasmore often the case for the infant group. These ﬁndings suggest
thatneonatal 7vPCVvaccination stimulatesTh2 responses,whereas
Th1 responses may be activated following immunizations at 1 and
2 months of age. We can conclude that, in contrast to neonatal BCG
vaccination, a neonatal dose of 7vPCV does not have the capacity
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o stimulate neonatal T-cells to generate signiﬁcant Th1 responses
21,22], at least not in this study population.
Variation in the Th1/Th2 response may inﬂuence the antibody
sotype and priming for B cell memory of vaccine-related pneu-
ococcal serotypes [12–14], but how this affects protection is
ot clear. In neonatal mice impaired Th2 cytokine responses have
een directly related to reduced antibody responses and protec-
ion against pneumococcal infections, whilst infantmice producing
h2 but no Th1 responses were able to resist challenges [20].
hus despite the inability to prime Th1 responses, the capacity of
eonatal 7vPCV vaccination to activate speciﬁc Th2 responses in
uman newborns could be sufﬁcient to stimulate functional anti-
ody responses and provide protection against invasive disease in
he ﬁrst weeks of life. The associations between neonatal 7vPCV-
nduced Th2 cytokine responses, antibody responses to 7vPCV
erotypes and risk of carriage and disease will be addressed in our
ngoing studies.
The skewing of Th2 responses following neonatal 7vPCV immu-
ization may be relevant to subsequent local reactions to 7vPCV
able 2
ffect of age at BCG vaccination on cytokine responses at 3 months.
CRM197
Coefﬁcient ˇ (95% CI) p-Value
L-5 0.003 (−0.018 to 0.023) 0.808
L-13 0.001 (−0.019 to 0.021) 0.928
FN- − 0.001 (−0.021 to 0.020) 0.940
L-10 − 0.002 (−0.023 to 0.018) 0.815
inear regression analysis was used to study associations between cytokine responses t
onths old and their age when they were vaccinated with BCG (independent variable).nth-old children in the neonatal 7vPCV (white bar), infant 7vPCV (grey bar) and
ression of IL-23, type-I interferon, Granzyme B and lymphotoxin-were measured
sent the geometric means and standard errors of geometric means of normalized
or DTP booster immunizations. We have previously shown that
Th2 skewing of cytokine responses to tetanus toxoid in associ-
ation with vaccine speciﬁc IgE was correlated with large local
reactions to diphtheria-tetanus-acellular pertussis boosters at 4
years of age [35]. In PNG this may be less relevant as DTwP
is used and booster immunizations are not given to older chil-
dren. Moreover, reactogenicity to 7vPCV immunization was low
in both study groups, in particular in the neonatal group, which
provides reassurance for the safety of 7vPCV immunization at
birth.
CRM197 is the product of a single missense mutation of diphthe-
ria toxin (DT) that attenuates its toxicity but not immunogenicity.
Immune responses to DT and CRM197 are therefore similar, but
in 7vPCV the immunogenicity of CRM197 may be reduced due to
conjugation of pneumococcal polysaccharides [12]. Although the
capacity of 7vPCV to induce memory T-cell responses in PNG new-
borns and infants is obvious from the signiﬁcantly elevated CRM197
responses compared to the control group, based on this study it
cannot be determined whether immunization with 7vPCV has an
PPD
Coefﬁcient ˇ (95% CI) p-Value
−0.017 (−0.039 to −0.004) 0.114
−0.023 (−0.044 to −0.002) 0.033
−0.016 (−0.037 to 0.005) 0.138
−0.013 (−0.035 to 0.009) 0.255
o the 7vPCV protein carrier CRM197 and PPD in study children when they were 3
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dditive, synergistic or suppressing effect on DT responses induced
y DTwP-Hib.
Although immunizationwith 7vPCV did not interferewith T cell
esponses to co-administered vaccines or with the maturation of T
ell responses in general, TLR-mediated responses were modulated
s shown by enhanced IL-6 and IL-10 responses in both 7vPCV vac-
ination groups. One possible explanation may be the presence of
luminium adjuvant (Alum) in the study vaccine. Although all chil-
ren receive Alum in the DTwP/Hib vaccine, this is as a hydroxide
alt rather than phosphate as is used in the 7vPCV. Recent stud-
es have shown that Alum induces the release of mature IL-1
36,37], which can stimulate IL-6 and IL-10 production [37–39],
nd may have a long-lasting and non-localized effect through cir-
ulation of inﬂammatory dendritic cells [37,40] that predominantly
nduce Th2 responses [37,41]. Althoughwewere not able to demon-
trate enhanced IL-1 responses in the 7vPCV vaccinated children,
his may be explained by ﬁndings that concomitant TLR and Alum
timulation is required to induce IL-1 secretion in vitro [36]. The
ersistence of this modulated innate immune response and the
otential effects of IL-10 and IL-6 on promoting tolerance [42,43]
nd Th17 development [44–46] will be the subject of future inves-
igations when the study children are older.
In summary, in this study we have demonstrated that
eonatal 7vPCV immunization primes carrier protein-speciﬁc Th2-
ssociated responses in PNG infants. The power of this study is
hat rather than studying non-speciﬁc immune responses that are
net outcome of a plethora of exposures to infections, environ-
ental antigens and other vaccinations, antigen-speciﬁc responses
ere analysed and bystander effectswere investigated. Accelerated
vPCV vaccination had no detectable bystander effects on T cell
esponses, but signiﬁcantly enhanced TLR-mediated IL-6 and IL-
0 responses. The potential implications of these skewed Th2 and
nnate immune responses on subsequent immune responses up to
ge 18 months are the subject of ongoing studies.
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